Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL5077832 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL27960743 | 1.00 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1741347 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL676375 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL4009914 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL47868 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20733 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1649601 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL21834714 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3041440 | 0.97 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674273-A1 | DAIRY ALTERNATIVE PLANT BASED FOOD PRODUCTS | Compagnie Gervais Danone (FR) | 2026-01-07 | — | — | EP | claimed |
| US-20240065306-A1 | SAUCE | UAB DAUMANTAI LT (LT) | 2024-02-29 | — | — | US | claimed |
| CN-114903985-A | Composition and application thereof in preventing and treating hyperoxaluria | 宁波倍益嘉生物科技有限公司 | 2022-08-16 | — | — | CN | claimed |
| US-11365334-B2 | Liquid de-icing brine suspension | ENVIROTECH SERVICES, INC. (US) | 2022-06-21 | — | — | US | claimed |
| WO-2022101732-A1 | SAUCE | UAB "DAUMANTAI LT" (LT) | 2022-05-19 | — | — | WO | claimed |
| US-20200299558-A1 | LIQUID DE-ICING BRINE SUSPENSION | ENVIROTECH SERVICES, INC. (US) | 2020-09-24 | — | — | US | claimed |
| EP-3349594-B1 | SALT SUBSTITUTE COMPOSITION AND USE THEREOF | PODRAVKA D D (HR) | 2020-04-22 | — | — | EP | claimed |
| US-10251909-B2 | Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-09 | — | — | US | claimed |
| EP-3349594-A1 | SALT SUBSTITUTE COMPOSITION, PREPARATION AND USE THEREOF | PODRAVKA d.d. (HR) | 2018-07-25 | — | — | EP | claimed |
| WO-2017046620-A1 | SALT SUBSTITUTE COMPOSITION, PREPARATION AND USE THEREOF | PODRAVKA D.D. (HR) | 2017-03-23 | — | — | WO | claimed |
| US-20050197402-A1 | Dietary supplementation with stoichiometrically specific potassium magnesium citrate | MISSION PHARMACAL CO. | 2005-09-08 | — | — | US | claimed |
| CN-1486969-A | Composite mineral salf of potassium-magnesium hydrogen citrate and its prepn process | 南京市鼓楼医院 | 2004-04-07 | — | — | CN | claimed |
| US-5432200-A | Method for increasing urinary excretion of electrolytes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1995-07-11 | — | — | US | claimed |
| EP-0429157-B1 | Dietary supplementation with potassium magnesium citrate | MISSION PHARMA CO (US) | 1995-03-22 | — | — | EP | claimed |
| EP-0380829-B1 | Magnesium potassium citrate | MISSION PHARMA CO (US) | 1994-06-22 | — | — | EP | claimed |
| US-5219889-A | Overcoming renal potassium and magnesium loss from thiazide treatment ; oral administering | THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-15 | — | — | US | claimed |
| EP-0429157-A2 | Dietary supplementation with potassium magnesium citrate | MISSION PHARMACAL COMPANY, INC. (US) | 1991-05-29 | — | — | EP | claimed |
| US-4985593-A | Dietary Supplement | MISSION PHARMACAL COMPANY, INC. (US) | 1991-01-15 | — | — | US | claimed |
| EP-0380829-A1 | Magnesium potassium citrate | MISSION PHARMACAL COMPANY, INC. (US) | 1990-08-08 | — | — | EP | claimed |
| US-4895980-A | Reacting citric acid with magnesium and potassium compounds | MISSION PHARMACAL COMPANY, INC. (US) | 1990-01-23 | — | — | US | claimed |